MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1186/s13613-023-01164-3

Медицинская библиотека · Annals of intensive care · 2023

Overview of the current use of levosimendan in France: a prospective observational cohort study.

Cholley Bernard, Bojan Mirela, Guillon Benoit, Besnier Emmanuel, Mattei Mathieu, Levy Bruno, Ouattara Alexandre, Tafer Nadir, Delmas Clément, Tonon David, Rozec Bertrand, Fellahi Jean-Luc, Lim Pascal, Labaste François, Roubille François, Caruba Thibaut, Mauriat Philippe, ARCOTHOVA study group

СтатьяПеревод в очереди

Аннотация

BACKGROUND

Following the results of randomized controlled trials on levosimendan, French health authorities requested an update of the current use and side-effects of this medication on a national scale.

METHOD: The France-LEVO registry was a prospective observational cohort study reflecting the indications, dosing regimens, and side-effects of levosimendan, as well as patient outcomes over a year.

RESULTS

The patients included (n = 602) represented 29.6% of the national yearly use of levosimendan in France. They were treated for cardiogenic shock (n = 250, 41.5%), decompensated heart failure (n = 127, 21.1%), cardiac surgery-related low cardiac output prophylaxis and/or treatment (n = 86, 14.3%), and weaning from veno-arterial extracorporeal membrane oxygenation (n = 82, 13.6%). They received 0.18 ± 0.07 µg/kg/min levosimendan over 26 ± 8 h. An initial bolus was administered in 45 patients (7.5%), 103 (17.1%) received repeated infusions, and 461 (76.6%) received inotropes and or vasoactive agents concomitantly. Hypotension was reported in 218 patients (36.2%), atrial fibrillation in 85 (14.1%), and serious adverse events in 17 (2.8%). 136 patients (22.6%) died in hospital, and 26 (4.3%) during the 90-day follow-up.

CONCLUSIONS

We observed that levosimendan was used in accordance with recent recommendations by French physicians. Hypotension and atrial fibrillation remained the most frequent side-effects, while serious adverse event potentially attributable to levosimendan were infrequent. The results suggest that this medication was safe and potentially associated with some benefit in the population studied.

Для цитирования: Cholley Bernard, Bojan Mirela, Guillon Benoit, Besnier Emmanuel, Mattei Mathieu, Levy Bruno, Ouattara Alexandre, Tafer Nadir, Delmas Clément, Tonon David, Rozec Bertrand, Fellahi Jean-Luc, Lim Pascal, Labaste François, Roubille François, Caruba Thibaut, Mauriat Philippe, ARCOTHOVA study group. Overview of the current use of levosimendan in France: a prospective observational cohort study.. Annals of intensive care. 2023. DOI: 10.1186/s13613-023-01164-3.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.